DABAT common mistakes
DABAT · Understand the traps and how to avoid them.
Calculating a serum osmolal gap with the formula 2[Na] + [glucose]/18 + [BUN]/2.8 and then treating any elevation as proof of toxic alcohol ingestion, without first correcting for the measured ethanol concentration.
Candidates memorize the osmolal gap as a 'toxic alcohol test' and forget that ethanol is the most common osmotically active xenobiotic and contributes roughly [EtOH]/3.7 to osmolality. They also forget that the gap is normal once the parent alcohol has been metabolized to acid, so a normal gap never excludes late-presenting ethylene glycol or methanol poisoning.
What to do instead
Always compute the osmolal gap as measured osmolality minus calculated osmolality, then subtract the ethanol contribution ([EtOH in mg/dL]/3.7) before interpreting. Pair every osmolal gap with an anion gap, urine microscopy for calcium oxalate crystals, and a volatile screen; interpret a normal osmolal gap with a high anion gap as late toxic alcohol poisoning, not as exclusion.
Applying the anion gap formula without correcting for hypoalbuminemia, then dismissing a high anion gap metabolic acidosis because the raw gap looks normal or only mildly elevated.
The standard AG = Na - (Cl + HCO3) assumes a normal albumin of about 4 g/dL. In critically ill, malnourished, or cirrhotic patients the albumin may be 2 g/dL, masking a large unmeasured anion load. Candidates also forget to add potassium or to use the correct reference range for their analyzer.
What to do instead
Use the albumin-corrected anion gap: AG corrected = AG measured + 2.5 x (4.0 - albumin in g/dL). Recompute on every set of electrolytes and trend it against the bicarbonate. If the corrected gap is elevated with a rising lactate, ketones, or osmolar gap, pursue toxic alcohol, salicylate, or metformin causes rather than attributing the acidosis to hypoperfusion alone.
Treating the half-life and volume of distribution from a single published case report as if they were population pharmacokinetic parameters, and using them to justify a specific hemodialysis duration or antidote dose.
Candidates conflate illustrative case data with validated pharmacokinetics, and they forget that Vd and clearance change with dose, saturable metabolism, renal function, and coingestants. This produces overconfident dosing and dialysis recommendations that do not match the patient's measured concentrations.
What to do instead
Distinguish first-order from zero-order (saturable) kinetics explicitly, and state which parameter is being estimated and from what data. For elimination decisions, use measured serial concentrations to calculate the patient's own half-life and clearance, then compare with published ranges. When evidence is limited, say so and base the plan on clinical trajectory plus repeat levels.
Recommending hemodialysis for any patient with a 'dialyzable' drug on a list, without checking that the drug has a small volume of distribution, low protein binding, and that the patient has a life-threatening indication such as refractory acidosis, deteriorating vital signs, or end-organ failure.
Candidates memorize antidote and dialysis lists as drug-name associations rather than as physiologically justified interventions. They skip the criteria of low Vd (roughly under 1 L/kg), low protein binding, adequate blood flow, and a clinical endpoint that dialysis will actually change.
What to do instead
For each enhanced-elimination question, run a four-part check: (1) pharmacokinetic suitability (Vd, protein binding, molecular size), (2) clinical indication (severe toxicity, refractory acidosis, renal or hepatic failure, deteriorating course), (3) whether an antidote or supportive care is sufficient, and (4) which modality (intermittent HD, CRRT, charcoal hemoperfusion) fits the toxin. Justify dialysis with the indication, not the drug name.
Choosing activated charcoal for every ingestion, including caustics, hydrocarbons, metals, alcohols, and patients with altered mental status or unprotected airway, and giving multiple doses without checking for ileus or obstruction.
Charcoal is taught as the universal decontamination step, so candidates apply it reflexively. They forget that charcoal does not adsorb alcohols, metals, or strong acids and bases, that aspiration pneumonitis is a serious risk with impaired airway protection, and that repeated dosing requires a functioning gut and is mainly justified for enterohepatic-recirculating drugs such as carbamazepine, theophylline, or dapsone.
What to do instead
Before recommending charcoal, confirm four things: the toxin is adsorbable, the ingestion is recent enough (generally within 1 to 2 hours, longer for sustained-release or enterohepatic drugs), the airway is protected or the patient is alert, and there is no contraindication such as caustic, hydrocarbon, or bowel obstruction. For repeated doses, document a reason and reassess bowel function and electrolytes.
Managing the poisoned patient by ordering a fixed 'tox screen' panel and waiting for results before treatment, rather than treating a compatible toxidrome on clinical grounds and using targeted tests to confirm or exclude specific diagnoses.
Candidates believe the comprehensive urine drug screen is definitive. In reality it is often immunoassay-based, has cross-reactivity and cutoff limitations, misses many drugs (most novel psychoactive substances, many synthetic opioids, gabapentinoids), has a long turnaround, and rarely changes acute management. Delaying naloxone, bicarbonate, or glucagon while waiting is harmful.
What to do instead
Identify the toxidrome first (opioid, sympathomimetic, anticholinergic, cholinergic, sedative-hypnotic, serotonergic, or withdrawal), start empiric treatment, and order targeted tests that change management: acetaminophen and salicylate levels, blood gas, electrolytes with anion and osmolar gaps, ECG, and specific immunoassays where relevant. Explain in the answer why the broad screen does not alter the acute plan.
Interpreting a urine drug screen positive for amphetamines or opioids as proof of the ingested agent, ignoring cross-reactivity (for example bupropion, pseudoephedrine, or labetalol on amphetamine immunoassays) and ignoring that the parent drug may be undetectable while metabolites persist.
Candidates treat immunoassay results as chemically specific. They also confuse detection windows with clinical effect and fail to consider that a positive result may reflect prescribed or incidental exposure rather than the cause of the current toxidrome.
What to do instead
For any positive immunoassay, ask what cross-reactants exist and whether confirmatory testing (GC-MS or LC-MS/MS) is needed. Correlate with the clinical picture and timing; a positive screen without a compatible syndrome should prompt a different explanation. When a specific drug is suspected and matters clinically, request the quantitative or confirmatory assay rather than relying on the screen.
Treating opioid withdrawal with escalating full-agonist opioids or, conversely, withholding buprenorphine because of the precipitated-withdrawal fear, without applying the Clinical Opiate Withdrawal Scale and appropriate induction timing.
Candidates learn that buprenorphine can precipitate withdrawal but not the practical threshold (moderate withdrawal, typically a COWS score around 8 to 12) or the role of low-dose induction. They also over-treat withdrawal with repeated short-acting opioids, which risks sedation and does not address the underlying disorder.
What to do instead
Score withdrawal objectively with COWS, treat symptomatically (clonidine or lofexidine, antiemetics, antidiarrheals, NSAIDs), and start buprenorphine once withdrawal is moderate, using low-dose or standard induction per protocol. For methadone, use a symptom-driven initial dose and reassess rather than stacking doses. Link every acute plan to a maintenance and harm-reduction plan.
Applying default uncertainty factors (10x for interspecies, 10x for intraspecies) and calling the result a safe dose, without stating the derivation, the critical study and endpoint, the route extrapolation, or the difference between an RfD, an MRL, and an occupational exposure limit.
Candidates memorize the 100-fold factor as a rule and skip the framework: identifying the critical effect, the point of departure (NOAEL, LOAEL, or benchmark dose), the database deficiencies, and the route and duration adjustments. They also conflate risk assessment outputs that are derived for different populations and exposure assumptions.
What to do instead
Walk through the sequence explicitly: hazard identification, dose-response with the critical study and endpoint, point of departure, uncertainty factors with justification for each, and the resulting reference value. State the target population and exposure route, and distinguish the RfD (chronic oral, general population) from the MRL (route- and duration-specific) and from the occupational limit (healthy workers, 8-hour shift).
Explaining a toxic mechanism with a vague statement such as 'it causes oxidative stress and cell death' instead of naming the molecular target, the affected pathway, and the dose- or time-dependence that links it to the clinical syndrome.
Candidates underprepare the mechanistic domain and fall back on generic phrases. This loses credit because it cannot explain why one exposure causes methemoglobinemia and another causes cholinesterase inhibition, why an antidote works, or why effects are delayed.
What to do instead
For each major toxicant, rehearse a three-part chain: the molecular initiating event (for example, cytochrome oxidase inhibition by cyanide, or hemoglobin oxidation by nitrites), the cellular consequence (histotoxic hypoxia, impaired oxygen delivery), and the clinical and laboratory signature with its time course. Then connect the antidote to the specific step it reverses (hydroxocobalamin binding cyanide, methylene blue reducing methemoglobin via NADPH).